From the Guidelines
The Gardasil HPV vaccine is typically administered in a two or three-dose schedule, with the recommended intervals being 0,2, and 6 months for individuals 15 years and older, and 0 and 6-12 months for individuals 9-14 years old, as supported by the most recent study 1.
Key Points to Consider
- The vaccine schedule is crucial in developing an optimal immune response against HPV strains.
- For individuals 9-14 years old, a two-dose schedule may be sufficient, with the second dose given 6-12 months after the first, as recommended by the ACIP 1.
- The immune response with a 12-month interval between the 2 doses was more robust than that measured when the interval was only 6 months, as shown in a randomized, controlled clinical study 1.
- The FDA approved the 2-dose schedule for persons 9 through 14 years of age on October 7,2016, and the ACIP revised its recommendation on October 19,2016 to vaccinate with 2 doses of 9vHPV vaccine 1.
Important Considerations
- The timing between doses helps the body build stronger and longer-lasting immunity against HPV strains.
- If doses are given too close together, the immune response may not be as robust, while excessively delayed doses might leave a person vulnerable to infection during the extended interval period.
- Always consult with your healthcare provider about the appropriate schedule for your specific situation, as they can provide personalized guidance based on your individual needs and circumstances.
- Health care provider recommendation and physician attitude play a major role in the decision to vaccinate against HPV, and a strong endorsement is more influential than a weak one 1.
From the Research
Gardasil Vaccine Interval
The Gardasil vaccine is administered in a series of doses to provide protection against human papillomavirus (HPV).
- The recommended interval for the Gardasil vaccine is not explicitly stated in the provided studies, but it is mentioned that the vaccine should be given as a 3-dose regimen when delivered to immunocompromised populations 2.
- A study on the immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children found that the vaccine was given to participants and serum anti-HPV antibody levels were measured at baseline, 7, and 24 months after the first dose of vaccine 3.
- However, the specific interval between doses is not provided in the study.
- Other studies discuss the importance of HPV vaccination in immunocompromised individuals, but do not provide information on the recommended interval between doses 4, 5, 6.